Skip to main content

Table 1 Incidences and Chi-squared based test for temporal trends in resistance

From: The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001–2006) in Portugal

   2001–'02 2002–'03 2003–'04 2004–'05 2005–'06 P-value
Multidrug resistance        
  n 33 30 22 21 13  
  N 576 574 583 626 490  
  incidence 5.7 5.2 3.8 3.4 2.7 0.003
  95%-CI 4.0 – 8.0 3.5 – 7.4 2.4 – 5.7 2.1 – 5.1 1.4 – 4.5  
Full class resistance        
NRTI n 78 63 53 40 29  
  N 576 572 578 619 476  
  incidence 13.5 11,0 9.2 6.5 6.1 <0.001
  95%-CI 10.9 – 16.6 8.6 – 13.8 6.9 – 11.8 4.7 – 8.7 4.1 – 8.6  
NNRTI n 203 226 258 245 187  
  N 570 557 541 560 445  
  incidence 35.6 40.6 47.7 43.8 42.0 0.011
  95%-CI 31.7 – 39.7 36.5 – 44.8 43.4 – 52.0 39.6 – 48.0 37.4 – 46.8  
PI n 60 50 32 40 35  
  N 574 570 572 611 479  
  incidence 10.5 8.8 5.6 6.5 7.3 0.013
  95%-CI 8.1 – 13.2 6.6 – 11.4 3.9 – 7.8 4.7 – 8.8 5.1 – 10.0  
  1. NRTI, nucleoside reverse-transcriptase inhibitors; NNRTI, nonnucleoside reverse-transcriptase inhibitors; PI, protease inhibitors.
  2. Multidrug resistance (MDR): at most 1 susceptible drug available over all classes; Full class resistance (FCR): no susceptible drugs available in a class.